Models of disease behavior in idiopathic pulmonary fibrosis

BMC Medicine

Harold R. Collard²  Brett Ley²  Kerri A. Johannson¹ 

[1] Department of Medicine, University of Calgary, 6th Floor - 4448 Front Street S.E., Calgary T3M-1M4, AB, Canada;Department of Medicine, University of California, San Francisco, Box 0111, 505 Parnassus Avenue, San Francisco 94143, CA, USA

关键词: Prognosis;    Interstitial lung disease;    Idiopathic pulmonary fibrosis;    Biological markers;   

Others  :  1227207
DOI  :  10.1186/s12916-015-0403-7

 received in 2015-04-15, accepted in 2015-06-19,  发布年份 2015

【 摘 要 】

Idiopathic pulmonary fibrosis is a diffuse parenchymal lung disease of unknown cause. The natural history of disease can vary considerably, making it difficult to predict the clinical trajectory for an individual patient. Accurate prognostication is desirable for clinical management as well as for cohort enrichment in clinical trials of therapeutics. Clinical and biomarker models of disease behavior have been developed to improve prognostication in idiopathic pulmonary fibrosis, with moderate predictive capabilities. Integrated prediction models that combine both clinical and biomarker variables will improve prognostication for patients and improved cohort enrichment strategies for clinical trials. This goal may be best achieved through collaborative patient registries with prospectively collected biological samples that allow for characterization of disease behavior in idiopathic pulmonary fibrosis.

【 授权许可】

   
2015 Johannson et al.

【 参考文献 】

• [1]Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK et al.. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183:788-824.
• [2]Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE et al.. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007; 176:636-43.
• [3]King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM. Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med. 2001; 164:1171-81.
• [4]Watters LC, King TE, Schwarz MI, Waldron JA, Stanford RE, Cherniack RM. A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1986; 133:97-103.
• [5]Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nicholson AG et al.. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med. 2003; 167:962-9.
• [6]du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A et al.. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184:459-66.
• [7]du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW et al.. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J. 2014; 43:1421-9.
• [8]Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS et al.. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012; 156:684-91.
• [9]Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH et al.. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014; 273:570-9.
• [10]Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015; 45:1374-81.
• [11]Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest. 2014; 146:1256-62.
• [12]Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014; 307:L681-91.
• [13]Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, Richards TJ et al.. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013; 309:2232-9.
• [14]Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS et al.. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014; 2:557-65.
• [15]Noth I, Zhang Y, Ma SF, Flores C, Barber M, Huang Y et al.. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013; 1:309-17.
• [16]Greene KE, King TE, Kuroki Y, Bucher-Bartelson B, Hunninghake GW, Newman LS et al.. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J. 2002; 19:439-46.
• [17]Barlo NP, van Moorsel CH, Ruven HJ, Zanen P, van den Bosch JM, Grutters JC. Surfactant protein-D predicts survival in patients with idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis. 2009; 26:155-61.
• [18]Song JW, Do KH, Jang SJ, Colby TV, Han S, Kim DS. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest. 2013; 143:1422-9.
• [19]Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K et al.. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158:1680-4.
• [20]Prasse A, Probst C, Bargagli E, Zissel G, Toews GB, Flaherty KR et al.. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179:717-23.
• [21]Vuga LJ, Tedrow JR, Pandit KV, Tan J, Kass DJ, Xue J et al.. C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014; 189:966-74.
• [22]DePianto DJ, Chandriani S, Abbas AR, Jia G, N’Diaye EN, Caplazi P et al.. Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax. 2015; 70:48-56.
• [23]Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D et al.. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 185:67-76.
• [24]Jaffar J, Unger S, Corte TJ, Keller M, Wolters PJ, Richeldi L et al.. Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Chest. 2014; 146:1055-63.
• [25]Kadota J, Mizunoe S, Mito K, Mukae H, Yoshioka S, Kawakami K et al.. High plasma concentrations of osteopontin in patients with interstitial pneumonia. Respir Med. 2005; 99:111-7.
• [26]Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA et al.. Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012; 303:L1046-56.
• [27]Okamoto M, Hoshino T, Kitasato Y, Sakazaki Y, Kawayama T, Fujimoto K et al.. Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias. Eur Respir J. 2011; 37:1119-27.
• [28]Jenkins RG, Simpson JK, Saini G, Bentley JH, Russell AM, Braybrooke R et al.. Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study. Lancet Respir Med. 2015; 3:462-72.
• [29]Kotsianidis I, Nakou E, Bouchliou I, Tzouvelekis A, Spanoudakis E, Steiropoulos P et al.. Global impairment of CD4 + CD25 + FOXP3+ regulatory T cells in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179:1121-30.
• [30]Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R et al.. Semaphorin 7a + regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-beta1-induced pulmonary fibrosis. Am J Respir Crit Care Med. 2013; 187:180-8.
• [31]Moeller A, Gilpin SE, Ask K, Cox G, Cook D, Gauldie J et al.. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009; 179:588-94.
• [32]Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky A, Schwarz MI et al.. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009; 135:1557-63.
• [33]White ES, Brown KK, Collard HR, Conoscenti CS, Cosgrove GP, Flaherty KR et al.. Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc. 2014; 11:1171-5.